Shares Outstanding Shares Outstanding n/a Close	158.75M
Shares Change (YoY) Shares Change (YoY) n/a Close	1.64%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.9%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	66.76%
Shares Floating Shares Floating n/a Close	n/a
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	310,220
FTD / Avg. Volume FTD / Avg. Volume n/a Close	10.99%

Short Selling Information

The latest short interest is 22.57M, so 14.22% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	22.57M
Short % of Shares Out Short % of Shares Out n/a Close	14.22%
Short % of Float Short % of Float n/a Close	18.59%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	5.72

Valuation Ratios

The PE ratio is 187.06 and the forward PE ratio is 20.83. TG Therapeutics's PEG ratio is 2.36.

PE Ratio PE Ratio n/a Close	187.06
Forward PE Forward PE n/a Close	20.83
PS Ratio PS Ratio n/a Close	13.29
Forward PS Forward PS n/a Close	3.8
PB Ratio PB Ratio n/a Close	19.67
P/FCF Ratio P/FCF Ratio n/a Close	-107.84
PEG Ratio PEG Ratio n/a Close	2.36

Financial Ratio History

Enterprise Valuation

TG Therapeutics has an Enterprise Value (EV) of 4.45B.

EV / Sales EV / Sales n/a Close	13.52
EV / EBITDA EV / EBITDA n/a Close	89.15
EV / EBIT EV / EBIT n/a Close	-109.79
EV / FCF EV / FCF n/a Close	-109.67

Financial Position

The company has a current ratio of 6.25, with a Debt / Equity ratio of 1.14.

Current Ratio Current Ratio n/a Close	6.25
Quick Ratio Quick Ratio n/a Close	5.03
Debt / Equity Debt / Equity n/a Close	1.14
Debt / EBITDA Debt / EBITDA n/a Close	5.1
Debt / FCF Debt / FCF n/a Close	-6.27
Interest Coverage Interest Coverage n/a Close	1.75

Financial Efficiency

Return on Equity is 10.52% and Return on Invested Capital is 7.84%.

Return on Equity Return on Equity n/a Close	10.52%
Return on Assets Return on Assets n/a Close	4.05%
Return on Invested Capital Return on Invested Capital n/a Close	7.84%
Revenue Per Employee Revenue Per Employee n/a Close	$934,670.45
Profits Per Employee Profits Per Employee n/a Close	$66,428.98
Employee Count Employee Count n/a Close	352
Asset Turnover Asset Turnover n/a Close	0.57
Inventory Turnover Inventory Turnover n/a Close	0.35

Taxes

Income Tax Income Tax n/a Close	2.21M
Effective Tax Rate Effective Tax Rate n/a Close	8.64%

Stock Price Statistics

The stock price has increased by 148.26% in the last 52 weeks. The beta is 1.94, so TG Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	1.94
52-Week Price Change 52-Week Price Change n/a Close	148.26%
50-Day Moving Average 50-Day Moving Average n/a Close	37.48
200-Day Moving Average 200-Day Moving Average n/a Close	31.41
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	62.67
Average Volume (20 Days) Average Volume (20 Days) n/a Close	2,823,419

Income Statement

In the last 12 months, TG Therapeutics had revenue of 329M and earned 23.38M in profits. Earnings per share was 0.16.

Revenue Revenue n/a Close	329M
Gross Profit Gross Profit n/a Close	290.52M
Operating Income Operating Income n/a Close	41.93M
Net Income Net Income n/a Close	23.38M
EBITDA EBITDA n/a Close	49.9M
EBIT EBIT n/a Close	49.62M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	0.16

Full Income Statement

Balance Sheet

The company has 179.89M in cash and 254.38M in debt, giving a net cash position of -74.49M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	179.89M
Total Debt Total Debt n/a Close	254.38M
Net Cash Net Cash n/a Close	-74.49M
Retained Earnings Retained Earnings n/a Close	-1.53B
Total Assets Total Assets n/a Close	656.69M
Working Capital Working Capital n/a Close	484.3M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -40.52M and capital expenditures -45K, giving a free cash flow of -40.56M.

Operating Cash Flow Operating Cash Flow n/a Close	-40.52M
Capital Expenditures Capital Expenditures n/a Close	-45K
Free Cash Flow Free Cash Flow n/a Close	-40.56M
FCF Per Share FCF Per Share n/a Close	-0.28

Full Cash Flow Statement

Margins

Gross margin is 88.3%, with operating and profit margins of 12.74% and 7.11%.

Gross Margin Gross Margin n/a Close	88.3%
Operating Margin Operating Margin n/a Close	12.74%
Pretax Margin Pretax Margin n/a Close	7.78%
Profit Margin Profit Margin n/a Close	7.11%
EBITDA Margin EBITDA Margin n/a Close	15.17%
EBIT Margin EBIT Margin n/a Close	12.74%
FCF Margin FCF Margin n/a Close	-12.33%

Dividends & Yields

TGTX does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	0.53%
FCF Yield FCF Yield n/a Close	-0.93%

Dividend Details

Analyst Forecast

The average price target for TGTX is $43, which is 9.6% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$43
Price Target Difference Price Target Difference n/a Close	9.6%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	2.35
Graham Upside Graham Upside n/a Close	-94.01%

Stock Splits

The last stock split was on Apr 30, 2012. It was a backward split with a ratio of 4:225.

Last Split Date Last Split Date n/a Close	Apr 30, 2012
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	4:225

Scores

Altman Z-Score Altman Z-Score n/a Close	6.69
Piotroski F-Score Piotroski F-Score n/a Close	3